Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Legacy Pharmaceuticals International
WARNING LETTER
•Legacy Pharmaceuticals International•September 28, 2007

Legacy Pharmaceuticals International – FDA Warning Letter, Sep 28, 2007

Record Details

The FDA issued a Warning Letter to Legacy Pharmaceuticals International following an inspection of its Puerto Rico facility from September 10-28, 2007, concerning the manufacture of Efudex Topical Cream 5%. The inspection revealed significant deviations from Current Good Manufacturing Practice (CGMP) Regulations (21 CFR Parts 210 and 211), rendering the drug adulterated under 21 U.S.C. § 351(a)(2)(B).

Key violations included the failure to establish adequate written procedures for production and process control (21 CFR § 211.100(a)), leading to product variability and a lack of process understanding. The firm also failed to establish scientifically sound specifications and test procedures (21 CFR § 211.160(b)), particularly for viscosity, despite observed correlations with physical stability. Furthermore, the three-year expiration date for Efudex was deemed invalid due to numerous lots failing assay and [redacted] content specifications during their expiry period (21 CFR § 211.137(a)). Finally, the Quality Control unit failed to adequately review production records, investigate errors, and ensure proper procedure implementation (21 CFR § 211.22(a) and (c)), specifically regarding uninvestigated temperature fluctuations.

The FDA requires prompt corrective actions within 15 working days, including a written explanation of steps taken to prevent recurrence and supporting documentation. Failure to comply may result in legal action, including seizure and injunction, and could impact federal contracts, export certificates, and pending drug applications. A reinspection will be necessary to verify compliance.

Company
Legacy Pharmaceuticals International
Inspection date
September 28, 2007
Product type
Drugs
Office
San Juan District Office
People
  • Maridalia Torres-Irizarry ( District Director )
  • Zaida Berrios
View Company Profile

ID · 94a3b9d8-aba3-4ea0-9d9d-180388a209f5

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.100(a)21 CFR 211.160(b)21 CFR 211.137(a)21 CFR 211.22(a)21 CFR 211.22(c)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Legacy Pharmaceuticals International
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.